X

TONIN COUGH SYRUP S

Product Information

Registration Status: Active

SIN09666P

TONIN COUGH SYRUP S is approved to be sold in Singapore with effective from 1998-07-03. It is marketed by SATO PHARMACEUTICAL (SINGAPORE) PTE LTD, with the registration number of SIN09666P.

This product contains Noscapine 300mg/30ml, and Guaifenesin 60mg/30ml in the form of SYRUP. It is approved for ORAL use.

This product is manufactured by SATO PHARMACEUTICAL CO LTD in JAPAN.

It is an Over-the-counter Medicine that can be freely obtained from any retailer

Product Reference
Loading...


Indication

Investigated for use/treatment in lymphoma (non-hodgkin's), leukemia (lymphoid), cancer/tumors (unspecified), and multiple myeloma.

Mechanism of Action

Noscapine's antitussive effects appear to be primarily mediated by its sigma receptor agonist activity. Evidence for this mechanism is suggested by experimental evidence in rats. Pretreatment with rimcazole, a sigma specific antagonist, causes a dose-dependent reduction in antitussive activity of noscapine.

Active Ingredient/Synonyms

CB3304 | Noscapine |


Source of information: Drugbank (External Link). Last updated on: 3rd July 18. *Trade Name used in the content below may not be the same as the HSA-registered product.


Description

An expectorant that also has some muscle relaxing action. It is used in many cough preparations. [PubChem]

Indication

Used to assist the expectoration of phlegm from the airways in acute respiratory tract infections.

Mechanism of Action

Guaifenesin may act as an irritant to gastric vagal receptors, and recruit efferent parasympathetic reflexes that cause glandular exocytosis of a less viscous mucus mixture. Cough may be provoked. This combination may flush tenacious, congealed mucopurulent material from obstructed small airways and lead to a temporary improvement in dyspnea or the work of breathing.

Pharmacokinetics

Absorption
Rapidly absorbed from the GI tract
Distribution
Metabolism
Rapidly hydrolyzed (60% within seven hours) and then excreted in the urine, with beta-(2-methoxyphenoxy)-lactic acid as its major urinary metabolite.
Elimination

Toxicity

LD50 1510 mg/kg (rat, oral)

Active Ingredient/Synonyms

Glyceryl guaiacolate | guaiphenesin | Hustosil | Guaifenesin |


Source of information: Drugbank (External Link). Last updated on: 3rd July 18. *Trade Name used in the content below may not be the same as the HSA-registered product.

References

  1. Health Science Authority of Singapore - Reclassified POM
  2. Drugbank

Pharmfair.com uses cookies to improve your browsing experience. We'll assume you're ok with this, but you can opt-out if you wish. Peace!